Dr. Dario Vignali is the Frank Dixon Chair in Cancer Immunology and Vice Chair and Professor of Immunology at University of Pittsburgh School of Medicine.  His lab studies various aspects of T cell regulation, and recently generated a new mouse model to target conventional CD4 T cells.
Read More
Dr. Anil Bhushan is a Professor at the University of California, San Francisco School of Medicine and Co-Founder of Deciduous Therapeutics, an aging therapeutics company developing a novel class of immune-modulatory therapies. His lab focuses on understanding how the immune system senses and tunes its response to senescent cells in disease and aging and was one of the first to show the role of clearing senescent cells in models of type 1 diabetes.
Read More
Dr. Jeffrey Bluestone is the CEO and President of Sonoma Biotherapeutics, a San Francisco and Seattle-based company leveraging the properties of regulatory T cells to create living cell therapies that restore the immune system back to its balanced, fully functioning state.
Read More
Dr. Marc Jenkins is a Regents and Distinguished McKnight University Professor in the Department of Microbiology and Immunology and the Director of the Center for Immunology at the University of Minnesota. Dr. Jenkins discovered that CD4+ T cells require CD28 as well as TCR to produce IL-2. The Jenkins lab is focused on the basic biology of CD4+ T lymphocytes.
Read More
Dr. Isaac Chiu is an Assistant Professor of Immunology at Harvard Medical School, studying the role of the nervous system in mediating inflammation and host defense. Dr. Tiphaine Voisin is a Postdoctoral Fellow at Harvard Medical School, specializing in somato-sensation and neuro-immunology. They recently published a paper in PNAS on the role of the CysLT2R receptor in acute and chronic itch.
Read More